About Octapharma Australia:
Octapharma Australia was established in 2004 as a locally managed subsidiary of Octapharma AG to serve and support the growing need for plasma derived blood products such as immunoglobulins for Australian patients. This was possible following the creation and signing of the National blood agreement and establishment of the National Blood Authority (NBA), a statutory agency within the Australian Government Health portfolio.
Octapharma was the first non-CSL company to be nationally contracted to supply imported immunoglobulin products to Australian patients. The team of passionate, experienced staff have helped supply Australian healthcare providers and their patients with immunoglobulins under NBA contracted supply arrangements for many years since then, providing in excess of 5 million grams of product. Today, the team at Octapharma Australia continue to work hard to help and support Australian patients to access and benefit from our life-saving products like octagam® 10%.
What we do:
Octapharma currently supplies octagam® 10% to Australian hospitals under the most recent NBA supply arrangements. As a result of the COVID-19 pandemic, medicines like immunoglobulins are under considerable global supply pressure and all pharmaceutical companies in this specialised field are working to ensure a global, steady supply of immunoglobulins is maintained for patients. You can learn more about these supply arrangements by visiting www.nba.gov.au
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983. Our philosophy and intention is simply to be the best at what we do.
Octapharma thrives as an organisation in which people take ownership, have integrity, demonstrate grounded and confident leadership, drive sustainability and entrepreneurship while being inspired to remain focused on the patients we serve.
We employ more than 10,000 people worldwide to support the treatment of patients in more than 118 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care (bleeding management and functional volume replacement)
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US, ensuring that we can source sufficient precious raw material to produce our medicines.
For more information visit our global website: www.octapharma.com